Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 18596733)


Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK.

Kidney Int. 2008 Sep;74(6):791-8. doi: 10.1038/ki.2008.295. Epub 2008 Jul 2.


Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.

McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM.

Am J Nephrol. 2013;37(6):549-58. doi: 10.1159/000351175. Epub 2013 May 25.


A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.

Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK.

Kidney Int. 2010 Feb;77(3):239-46. doi: 10.1038/ki.2009.415. Epub 2009 Nov 4.


Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA.

Am J Kidney Dis. 2012 Sep;60(3):390-401. doi: 10.1053/j.ajkd.2012.03.009. Epub 2012 Apr 25.


Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. doi: 10.2215/CJN.04601007. Epub 2008 Apr 16.


Correction of anemia with epoetin alfa in chronic kidney disease.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators.

N Engl J Med. 2006 Nov 16;355(20):2085-98.


Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis.

Bárány P, Clyne N, Hylander B, Johansson AC, Simonsen O, Larsson R, Frisenette-Fich C, Svensson B, Helmers C.

Perit Dial Int. 1995;15(1):54-60.


Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.

Biggar P, Ketteler M, Hennemann H, Dömling R.

Clin Nephrol. 2008 Mar;69(3):185-92.


The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6. Epub 2012 Jul 3.


A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P.

Clin J Am Soc Nephrol. 2009 Nov;4(11):1731-40. doi: 10.2215/CJN.03470509. Epub 2009 Sep 17.


Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease.

De Nicola L, Conte G, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Tirino G, Avino D, Catapano F, Minutolo R.

Clin J Am Soc Nephrol. 2007 Sep;2(5):938-46.


Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.


Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014. Epub 2012 Aug 22.


A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.

Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M; Epoetin Alfa Extended Dosing Study Group.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1015-21. doi: 10.2215/CJN.05681207. Epub 2008 Apr 9.


Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L.

Clin J Am Soc Nephrol. 2009 Mar;4(3):552-9. doi: 10.2215/CJN.04380808. Epub 2009 Mar 4.


Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.

Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.

Am J Kidney Dis. 2005 Sep;46(3):481-8.


Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.

Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo-PASS study group.

Clin Nephrol. 2012 Jul;78(1):24-32.


What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?

Singh AK.

Curr Opin Nephrol Hypertens. 2010 Sep;19(5):420-4. doi: 10.1097/MNH.0b013e32833cf1d6. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk